NBTX - שווי שוק לנפח מכירות Nanobiotix SA

The P/S ratio of Nanobiotix S.A. (NBTX) reflects market capitalization relative to revenue, and this metric has reached 159.90. Nanobiotix S.A. is developing a physical foundation for oncology treatment by investing in nanoparticles to enhance radiation therapy. This cross-disciplinary technology enables the targeted destruction of tumors while preserving healthy cells. Currently, these innovative drugs are undergoing final testing prior to a commercial launch via strategic partnerships.

The P/S ratio determines the market value of one dollar of revenue, allowing an investor to assess the degree of asset overheating through the ratio of market capitalization to annual sales volume. By analyzing the history of P/S values, one can observe how the market prices in the future pricing power of Nanobiotix S.A. (NBTX), based on inelastic demand and the uniqueness of NBTXR3 nanoparticles for the physical destruction of tumors.